Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Approved Endocrinology Drugs in Clinical Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Aspargo Laboratories

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Aspargo Laboratories Announces Successful Completion of Pre-IND Meeting with FDA on Sildenafil Oral Spray to Treat Erectile Dysfunction

              Contact the Supplier

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Endocrinology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2020

              Details:

              FDA supported Aspargo’s plan to conduct a single dose bioequivalent study to assess the pharmacokinetics, bioequivalency, tolerability and safety of the Company’s Sildenafil Oral Spray drug candidate.

              Recordati

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ITALY Italy

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Recordati Submits New Drug Application for ISTURISA® in Japan

              Contact the Supplier

              Lead Product(s): Osilodrostat

              Therapeutic Area: Endocrinology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 26, 2020

              Details:

              In the Phase 3 LINC?3 study, a significantly higher proportion of patients treated with Isturisa® (osilodrostat) maintained normal mean urinary free cortisol (mUFC) at the end of the 8?week.

              Ro

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorize...

              Contact the Supplier

              Lead Product(s): Sildenafil Citrate

              Therapeutic Area: Endocrinology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Greenstone LLC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 23, 2020

              Details:

              Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer’s quality manufacturing standards and supply chain excellence.

              BeiGene

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

              Contact the Supplier

              Lead Product(s): Denosumab,0

              Therapeutic Area: Endocrinology

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amgen Inc

              Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million

              Deal Type: Collaboration January 02, 2020

              Details:

              The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.

              PharmaCompass__DigitalAd